Phio Announces Data Showcasing INTASYL’s Role in Helping Immune Cells Target and Kill Cancer Cells

Oct 7, 2024 | Press Releases

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts–(Newsfile Corp. – October 7, 2024) – Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT’s 2024 Advancing Gene + Cell Therapies for Cancer Conference

Oct 1, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – October 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more...

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 25, 2024 | Press Releases

–Data will be presented at the conference in October in MontrealMarlborough, Massachusetts–(Newsfile Corp. – September 25, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL®...

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 16, 2024 | Press Releases

Phio’s INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts–(Newsfile Corp. – September 16, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology...

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 9, 2024 | Press Releases

Conference to be held in New York City September 9-11thMarlborough, Massachusetts–(Newsfile Corp. – September 9, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene...